Jerry Durso | President and CEO |
Linda Richardson | Chief Commercial Officer |
Michelle Berrey | President of Research and Development and Chief Medical Officer |
Andrew Saik | CFO |
Gail Cawkwell | SVP, Medical Affairs, Safety & Pharmacovigilance |
Paul Nitschmann | SVP Regulatory Affairs |
Lisa DeFrancesco | SVP, Corporate Affairs and IR |
Anvita Gupta | Cowen and Company |
Swapnil Malekar | Piper Sandler |
Michael Lee | Jefferies |
Brian Abrahams | RBC Capital Markets |
Emily Bodnar | Cantor Fitzgerald |
Joseph Stringer | Needham & Company |
Salveen Richter | Goldman Sachs |
Ellie Merle | UBS |
Aspen Mori | Bank of America |
Matthew Luchini | BMO |
Thomas Smith | SVB Leerink |
Mayank Mamtani | B. Riley Securities |
Jay Olson | Oppenheimer |
Brian Skorney | Baird |
Ladies and gentlemen, thank you for standing by, and welcome to the Q3 2021 Intercept Pharmaceuticals Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]. I will now turn the call over to your host, Lisa DeFrancesco, SVP, Investor Relations and Corporate Affairs.